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Suppression of pain and inflammation still continues to be a challenge despite the
availability of a number of non-steroidal anti-inflammatory drugs (NSAIDs). This is be-
cause NSAIDs do not only exhibit a different spectrum of analgesic, anti-pyretic and
anti-inflammatory effects but also cause gastrointestinal (GI) complications ranging
from dyspepsia to fatal upper GI tract bleeding and perforation (1). Efforts to improve
the adverse effect profile of the current NSAIDs have been focused on developing pro-
drugs (2) or modifications of marketed formulations (3). These approaches have been
only partially successful. A recent approach is development of selective cyclooxygenase
(COX)-2 inhibitors (4–6). COX is the key enzyme that catalyzes the conversion of ara-
chidonic acid to prostaglandins and thromboxans. There are two types of cyclooxyge-
nase enzymes, COX-1 and COX-2. Currently available NSAIDs inhibit both COX-1 and
COX-2 enzymes. Inhibition of COX-1 reduces basal production of cytoprotective prosta-
glandins (PGs) PGE2 and PGI2 and hence causes ulceration while inhibition of COX-2
inhibits inflammation. Complete inhibition of COX-1 is therefore not preferred and drugs
that inhibit the COX-2 enzyme are better anti-inflammatory agents (7, 8).
Owing to the continuous efforts in exploring the structural insights to aid the de-
sign (9, 10) and synthesis of safer novel anti-inflammatory agents, 2-amino-5-sulfanyl-
-1,3,4-thiadiazole was identified as the central nucleus. To date, 2-amino-5-sulfanyl-
-1,3,4-thiadiazole derivatives have not been reported to exhibit anti-inflammatory and
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A new series of cyclooxygenase-2 inhibitors with 2-amino-
-5-sulfanyl-1,3,4-thiadiazole as the central scaffold unit
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were characterized by analytical and spectral methods.
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analgesic activity. For this reason, it was thought worthwhile to synthesize a series of
diaryl substituted 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives, and perform their
pharmacological testing.
EXPERIMENTAL
Melting points were determined in an open capillary tube and were uncorrected.
Purity of the compounds was checked on pre-coated silica gel G plates (0.2 mm thick-
ness, Merck, India) using iodine vapor as visualizing agent. Infrared spectra were recor-
ded on a Perkin Elmer Paragon 1000 IR spectrometer (USA) and 1H spectra were obtai-
ned on a Bruker DRX-300 MHz FT NMR spectrometer (USA). Mass spectra were recor-
ded on a Jeol SX-102 mass spectrometer (Japan). Elemental analyses of the synthesized
compounds were obtained on an Elemental Vario EL II /Carlo N 1108 (Italy). All the re-
agents used in the present work were of synthetic grade (Aldrich, Germany, Lancaster,
UK).
The synthetic pathway is given in Scheme I (11) and characterization data of com-
pounds are given in Table I.
Synthesis of 4-5-chlorophenylamino)-1,3,4-thiadiazole-2-yl-sulphanyl-benzene
sulphonamide (1)
2-Amino-5-sulfanyl-1,3,4-thiadiazole (0.01 mol, 1.31 g) was suspended in a minimum
quantity of water and a sufficient quantity of 85% KOH solution was added under stir-
ring at room temperature. After a few minutes (5–10), the solution was brought to 0 °C
in an ice bath and 4-chlorobenzene sulfonamide (ArCl) (0.01 mol, 1.92 g) was added un-
der vigorous stirring. The reaction mixture was checked by thin layer chromatography.
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ArCl: 4-chlorobenzene sulfonamide (1, 3, 5, 7, 9, 11, 14, 15) or 4-chlorobenzene sulfonylchloride
(2, 4, 6, 8, 10, 12, 13). Ar1Cl: 1,4-disubstituted benzene 1,4-dichlorobenzene (1, 2),
1-bromo-4-chlorobenzene (3, 4), 1-chloro-4-flurobenzene (5, 6), 1-chloro-4-methylbenzene (7, 8),
1-chloro-4-trifluromethylbenzene (9, 10), 1-chloro-4-trichloromethylbenzene (11, 12),
4-chlorobenzene sulfonylchloride (13, 14), 4-chlorobenzene sulfonamide (15)
Scheme I
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The solution was neutralized upon completion of the reaction. The precipitate of 4-5-
-amino-(1,3,4)thiadiazole-2-yl-sulphanyl-benzene sulphonamide formed slowly. It was
filtered, washed with distilled water and crystallized using ether as a solvent. The pu-
rity of the synthesized intermediate was ascertained by thin layer chromatography us-
ing a methanol and xylene mixture (4:6, V/V). The intermediate (0.01 mol; 2.88 g) was
dissolved in ether and 1,4-dichlorobenzene (0.01 mol, 1.48 g) was added under stirring
while maintaining the temperature between 0–5 °C. After 30 minutes, water was added,
and a precipitate was formed. Filtration of the compound and recrystallization from
ether yielded compound 1. Compounds 2–15 were synthesized in a similar way.
Colorimetric COX (ovine) inhibitor screening assay
All synthesized compounds were evaluated for COX-1 and COX-2 inhibitory activity
by the colorimetric COX (ovine) inhibitor screening assay (13). It utilizes the peroxidase
component of cyclooxygenase. The peroxidase activity was assayed colorimetrically by
monitoring the appearance of oxidized N,N,N,N-tetramethyl-p-phenylenediamine (TMPD)
at 590 nm. This assay measures the heme-catalyzed hydroperoxidase activity of ovine
cyclooxygenase. The percentage of COX-1 and COX-2 inhibition is reported in Table II.
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1 –SO2NH2 –Cl 97.17  0.01 3.43  0.02
2 –SO2Cl –Cl 100.00  0.03 87.85  0.04
3 –SO2NH2 –Br 56.50  0.03 12.15  0.02
4 –SO2Cl –Br 70.12  0.01 60.74  0.01
5 –SO2NH2 –F –41.24  0.03 14.95  0.04
6 –SO2Cl –F 100.00  0.02 100.00  0.01
7 –SO2NH2 –CH3 –91.52  0.01 22.74  0.03
8 –SO2Cl –CH3 100.00  0.01 100.00  0.01
9 –SO2NH2 –CF3 –119.25  0.02 8.10  0.01
10 –SO2Cl –CF3 100.00  0.03 100.00  0.02
11 –SO2NH2 –CCl3 –85.87  0.03 –20.87  0.02
12 –SO2Cl –CCl3 100.00  0.04 100.00  0.03
13 –SO2Cl –SO2Cl 100.00  0.03 100.00  0.02
14 –SO2NH2 –SO2Cl –110.17  0.03 42.36  0.01
15 –SO2NH2 –SO2NH2 100.00  0.01 100.00  0.02
Indomethacin – – 100.00  0.02 97.00  0.01
Celecoxib – – 0.00 100.00  0.01
a 0.1 nmol applied
b Mean  SEM, n = 3.
The inhibitory activity was measured on a Bio Rad 550 (India) plate reader, on a
plate consisting of ninety wells. First, three wells were marked as background wells,
then three wells were marked as 100% initial activity wells and the remaining fifty-one
wells were marked as inhibitor wells. To the background wells, 160 mL buffer (0.1 mol
L–1 Tris HCl, pH 8), 10 mL heme and 10 mL DMSO were added; 150 mL buffer, 10 mL
heme, 10 mL DMSO and 10 mL of COX-1 enzyme were added to 100% initial activity
wells; 150 mL buffer, 10 mL heme, 10 mL of COX-1 and 10 mL of 10 m mol L–1 solution of
test compound 1 in DMSO were added to the other three wells. In the same manner, the
remaining forty-eight wells were prepared for test compounds 2 to 15, indomethacin
and celecoxib, respectively. The plate was carefully shaken for a few seconds and incu-
bated for 5 minutes at 25 °C. Finally, 20 mL TMPD and 20 mL arachidonic acid were added
to all fifty-seven wells. The plate was shaken again and incubated for 5 minutes at 25 °C.
The absorbance was noted at 590 nm and percentage inhibition was calculated. The pro-
cedure was repeated three times.
The COX-2 inhibitory activity was determined as discussed above; here COX-2 en-
zyme was used instead of COX-1 enzyme.
Anti-inflammatory activity
Anti-inflammatory activity of all synthesized compounds was determined by the
carrageenean-induced rat paw oedema test as described by Winter et al. (14). Albino rats
of Wistar strain (150–200 g) of both sexes were divided into different groups (control,
test and standard) containing six animals each. The animals were housed in standard
polypropylene cages under standard laboratory conditions (12:12 hour light/dark cycle
at 25  2 °C). They had free access to standard commercial diet and water. Ethical guide-
lines for the investigations of animals used in experiments were followed in all tests and
the institutional Ethical Committee Approval was provided. The test and standard com-
pounds were suspended in 1% carboxymethyl cellulose and administered orally to each
animal using a gastric gavage needle. The control group animals, however, received the
same volume of vehicle (1% carboxymethyl cellulose). One hour after the compounds
were administered, carrageenean was injected into the subplantar surface of the right
hind paw of animals. In this study, the animals were administered a 56 mg kg–1 (body
mass) dose of the test drug and 10 mg kg–1 (body mass) dose of the standard drug indo-
methacin. The paw volume was measured immediately using a plethysmometer (initial
paw volume) and thereafter the paw volume was measured 3 hours and 6 hours after
the administration of carrageenean. Percent paw oedema inhibition is reported in Table III.
Analgesic activity
The analgesic activity was measured by the tail flick method (15), using a radiant
type analgesiometer. The basal reaction time to radiant heat was taken by placing the tip
of the tail on the radiant heat source. Swiss albino mice (25–30 g) of either sex were di-
vided into seventeen groups containing six animals each. Animals were housed in stan-
dard polypropylene cages under standard laboratory conditions (12:12 hour light/dark
cycle at 25  2 °C). They had free access to standard commercial diet and water. For each
animal, the tail flick reaction time was obtained thrice before drug administration and
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the mean was used as the pre-drug reaction time. After administration of the drug, the
tail flick reaction times were measured after 30, 60, 90 and 180 minutes. The first group
served as control and the animals were administered the vehicle (10% Tween 20). The
second group of animals was administered 22.8 mg kg–1 (body mass) standard drug
(tramadol hydrochloride). The animals of the third to seventeenth group were treated
with 30 mg kg–1 (body mass) dose of the test drugs 1–15. Increase in the tail flick reac-
tion time after the administration of test drugs and standard drug were calculated for
30, 60, 90 and 180 minutes (Fig. 1).
RESULTS AND DISCUSSION
2-Amino-5-sulfanyl-1,3,4-thiadiazole reacted with potassium hydroxide to afford a
water soluble weak salt with an electron rich center and reacted with electron deficient
4-chlorobenzene sulphonamide to yield the intermediate 4-(5-amino-1,3,4-thiadiazole-
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Table III. Anti-inflammatory activity of synthesized compounds 1 to 15 on
carrageenen induced rat paw edema
Compd.
No.
Inhibition of paw oedema
after 3 hours (%)a,b
Inhibition of paw oedema
after 6 hours (%)b
Control – –
1 15.11 ± 0.02 10.41  0.01
2 46.51  0.01 34.37  0.01
3 23.25  0.01 16.66  0.02
4 38.37  0.02 31.25  0.01
5 26.74  0.02 20.83  0.02
6 61.62  0.02 47.91  0.02
7 41.86  0.01 34.37  0.02
8 65.11  0.01 44.79  0.02
9 18.60  0.02 13.54  0.02
10 61.62  0.01 52.08  0.02
11 00.00 –4.16  0.01
12 65.11  0.01 44.79  0.01
13 61.62  0.02 41.66  0.02
14 53.48  0.02 47.91  0.03
15 63.95  0.01 50.00  0.01
Indomethacin 76.74  0.01 58.33  0.02
a Dose for 1–15: 56 mg kg–1 b.m.
Dose for indomethacin 10 mg kg–1 b.m.
b Mean  SEM, n = 6.
-2-yl-sulphanyl)-benzene sulphonamide. The reaction was slow at the initial stage but
the formation of KCl enhanced the reaction rate. The intermediate was then subjected to
electrophillic substitution reaction with the electron deficient moiety 1,4-dichlorobenzene.
It afforded compound 1 and similarly compounds 2–15 (11). Elemental analyses data
and spectral data of all the synthesized compounds are in agreement with the assigned
structure (Table I).
In vitro inhibition of COX-1 and COX-2 enzyme data (Table II) indicate that com-
pounds 5, 7, 9 and 14 were selective inhibitors of COX-2 and potentiated the activity of
COX-1 enzyme (16). Among the above four compounds, 14 showed the highest selective
inhibitory activity against COX-2 enzyme (42.4%). All the four compounds possess the
sulphonamide group, which is in agreement with the established fact that sulphonamide
group is a required pharmacophore for selective inhibition of COX-2 enzyme. However,
compounds 6, 8, 10, 12, 13 and 15 showed non-selective COX inhibitory activity; they
showed 100% inhibition against COX-1 and COX-2 enzymes. Compounds 1, 2, 3 and 4
showed selective inhibitory activity against COX-1 enzymes. The percentage inhibition
of COX-1 and COX-2 by compound 2 is comparable to that of the standard drug indo-
methacin. Most interesting activity was found in compounds 11 and 12. Compound 11
was found to potentiate the activity of COX-1 and COX-2 enzymes while replacement of
–SO2NH2 in 11 by –SO2Cl in 12 made it a non-selective COX inhibitor.
Inflammation induced by carrageenean involves three distinct phases of mediator
release, including serotonin and histamine in the first phase (0–2 hours), kinins in the
second phase (3 hours) and prostaglandin in the third phase (0–4 hours). The results of
this study indicate that compounds 6, 8, 10, 12, 13 and 14 protected the paw oedema in
rat by 54 to 65% after 3 hours and 45 to 52% after 6 hours, while other tested compounds
showed lower anti-inflammatory activity compared to indomethacin (Table III). This su-
ggests that the presence of –SO2Cl is also favorable for anti-inflammatory and analgesic
activity. The same compounds showed analgesic activity comparable to that of tramadol
hydrochloride (Fig. 1).
324































Fig. 1. Analgesic activity (tail flick) (mean post drug reaction  SEM, n = 6).
CONCLUSIONS
Compound 14 4-5-(4-sulfamoyl-phenylsulphanyl)-1,3,4-thiadiazole-2-yl-amino-
benzene sulphonyl chloride can be selected for further studies since it contains sulpho-
namide as well as sulphonyl group; it showed the highest percentage of COX-2 inhibi-
tion and significant anti-inflammatory and analgesic activity compared to indomethacin
and tramadol hydrochloride, respectively.
REFERENCES
1. M. C. Allison, A. G. Howastan, C. J. Torrance, F. D. Lee and R. N. Russell, Gastrointestinal dam-
age associated with the use of nonsteroidal anti-inflammatory drugs, Engl. J. Med. 327 (1982)
749–754.
2. D. Bohl, H. Gaussmann, G. Vorberg, J. Sanch, R. Garcia-Barbal, J. F. Sarti and F. J. J. Harrison,
A clinical trial comparing a new NSAID: Droxicam and proxicam in spinal osteoarthritis, Int. J.
Clin. Pharmacol. Ther. Toxic. 28 (1990) 416–419.
3. R. S. Shelley and Y. Wei, Solutions of Aryl or Heteroaryl Substituted Alkanoic Acids in Lipo-
philic Solvents and Soft Gelatin Capsules Containing Such Solutions, Eur. Pat. Pub., 30 Nov.
1995, WO, 9531979, 1994.
4. K. Chegaev, L. Lazzarato, P. Tosco, C. Cena, E. Marini, B. Rolando, P. A. Carrupt, R. Fruttero
and A. Gasco, NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles en-
dowed with COX-2 inhibitory and vasodilatory properties, J. Med. Chem. 50 (2007) 1449–1457;
DOI: 10.1021/jm0607247.
5. M. Biava, G. C. Porretta, G. Poce, S. Supino, S. Forli, M. Rovini, A. Cappelli, F. Manetti, M. Botta,
L. Sautebin, A. Rossi, C. Pergola, C. Ghelardini, E. Vivoli, F. Makovec, P. Anzellotti, P. Patrigna-
ni and M. Anzini, Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced
inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-
-1 selectivity, J. Med. Chem. 50 (2007) 5403–5411; DOI: 10.1021/jm0707525.
6. J. P. Waldo and R. C. Larock, The synthesis of highly substituted isoxazoles by electrophilic cy-
clization: An efficient synthesis of valdecoxib, J. Org. Chem. 72 (2007) 9643–9647; DOI: 10.1021/
jo701942e.
7. J. R. Vane, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs,
Nature (New Biol.) 231 (1971) 232–235.
8. J. A. Mitchell, P. Akaraseenont, C. Themermann, R. J. Flower, J. R. Vane, Selectivity of non stero-
idal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase, Proc.
Natl. Acd. Sci. USA. 90 (1993) 11693–11697.
9. R. Sharma and S. C. Chaturvedi, Development of pharmacophoric models on 5,6-diarylimidaxo-
2,1-b-thiazole for selective cyclooxygenase-2 inhibitors, Indian J. Pharm. Sci. 66 (2004) 758–772.
10. R. Sharma, S. C. Chaturvedi and A. K. Saxena, 3D-QSAR studies on novel terphenyls for selec-
tive inhibition of cyclooxygenase-2 enzyme, Indian J. Pharm. Sci. 66 (2004) 758–772.
11. F. Clerici and D. Pocar, Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evalu-
ation of their antidepressant and anxiolytic activity, J. Med. Chem. 44 (2001) 931–936; DOI: 10.
1021/jm001027w.
12. R. J. Kulmacz and W. E. M. Lands, Requirements for hydro peroxide by the cyclooxygenase and
peroxidase activities of prostaglandin H synthase, Prostaglandins 25 (1983) 531–540.
325
R. Sharma et al.: 2-Amino-5-sulfanyl-1,3,4-thiadiazoles: A new series of selective cyclooxygenase-2 inhibitors, Acta Pharm. 58 (2008)
317–326.
13. Colorimetric COX (ovine) inhibitor screening assay, Catalog No. 760111, Cayman Chemical, Ann
Arbor (MI) 2005.
14. C. A. Winter, E. A. Risely and G. N. Nuss, Carrageenean-induced edema in hind paw of the rat
as an assay for anti-inflammatory drugs, Proc. Soc. Exp. Biol. 111 (1962) 544–547.
15. H. G. Vogel, Drug Discovery and Evaluation Pharmacological Assays, Springer, Frankfurt 2002, pp.
694.
16. R. R Ranatunge, M. Augustyniak, U. K. Bandarage, R. A. Earl, J. L. Ellis, D. S. Garvey, D. R.
Janero, L. G. Letts, A. M. Martino, M. G Murty, S. K. Richardson, J. D. Schroeder, M. J. Shum-
way, S. W. Tam, A. M. Trocha and D. V. Young, Synthesis and selective cyclooxygenase-2 inhibi-
tory activity of a series of novel, nitric oxide donor containing pyrazoles, J. Med. Chem. 47 (2004)
2180–2193; DOI: 10.1021/jm0302769.
S A @ E T A K
2-Amino-5-sulfanil-1,3,4-tiadiazoli: Nova serija selektivnih
inhibitora ciklooksigenaze-2
RAJESH SHARMA, JITENDRA SAINY i SUBHASH CHANDRA CHATURVEDI
Sintetizirana je nova serija inhibitora ciklooksigenaze-2 s 2-amino-5-sulfanil-1,3,4-tia-
diazolom. Novi spojevi karakterizirani su uobi~ajenim analiti~kim i spektroskopskim me-
todama. Sintetiziranim spojevima ispitana je sposobnost inhibicije ciklooksigenaze kolo-
rimetrijskim COX testom (gove|i COX), protuupalno djelovanje na edem {ape induciran
karageninom i analgetsko djelovanje metodom pomicanja repa. Neki su spojevi pokazali
zna~ajno biolo{ko djelovanje.
Klju~ne rije~i: 2-amino-5-sulfanil-1,3,4-tiadiazoli, ciklooksigenaza-1, ciklooksigenaza-2, protuupalno
djelovanje, analgetsko djelovanje
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